Heart Seat measures heart rate and oxygen saturation (SpO2). Casana also has partnerships with researchers to conduct validation studies for further clinical measurements. The company plans to file for future indications this year, including systolic and diastolic blood pressure.
Casana aims to initiate the market launch for Heart Seat by the end of 2023.
According to Casana’s website, the Heart Seat passively captures health parameters. It aims to reliably track health trends with no behavior change.
When used, the system unobtrusively gathers health data and analyzes it in context to provide insights into health and trends over time. It then sends data to the designated care team’s dashboard, designed in collaboration with Casana’s partners.
The company said it hopes to provide practitioners with reliable, clear trends within real-life context. These enable quicker reactions to help patients stay healthier at home.
“This clearance is a critical step on our journey to commercialize the Heart Seat,” said Casana CEO Austin McChord. “This brings us one step closer to helping patients and healthcare providers across the U.S. manage their health at home.”
